Xencor (NASDAQ:XNCR) Stock Price Up 6.3%

Xencor, Inc. (NASDAQ:XNCR)’s share price traded up 6.3% during mid-day trading on Monday . The company traded as high as $21.35 and last traded at $21.24. 325,761 shares were traded during mid-day trading, a decline of 52% from the average session volume of 679,953 shares. The stock had previously closed at $19.98.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $24.00 price target (down previously from $37.00) on shares of Xencor in a research note on Wednesday, February 28th. BMO Capital Markets lowered their price target on Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. Royal Bank of Canada restated an “outperform” rating and issued a $32.00 price objective on shares of Xencor in a report on Wednesday, February 28th. Wedbush decreased their target price on Xencor from $36.00 to $34.00 and set an “outperform” rating for the company in a report on Wednesday, February 28th. Finally, Mizuho dropped their target price on shares of Xencor from $59.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, January 22nd. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Xencor presently has an average rating of “Moderate Buy” and an average price target of $36.00.

Xencor Stock Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.36 and a current ratio of 7.36. The stock has a fifty day simple moving average of $21.91 and a two-hundred day simple moving average of $20.39. The stock has a market cap of $1.48 billion, a PE ratio of -10.87 and a beta of 0.76.

Xencor (NASDAQ:XNCR) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of $0.36 by ($0.67). Xencor had a negative net margin of 74.90% and a negative return on equity of 18.67%. The firm had revenue of $44.70 million during the quarter, compared to analysts’ expectations of $77.63 million. During the same quarter last year, the company posted ($0.20) earnings per share. Xencor’s revenue for the quarter was up 106.9% compared to the same quarter last year. Equities analysts anticipate that Xencor, Inc. will post -3.25 EPS for the current fiscal year.

Insider Activity

In related news, VP John R. Desjarlais sold 54,108 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total value of $1,048,613.04. Following the completion of the transaction, the vice president now owns 161,675 shares of the company’s stock, valued at $3,133,261.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP John R. Desjarlais sold 54,108 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $19.38, for a total value of $1,048,613.04. Following the sale, the vice president now directly owns 161,675 shares of the company’s stock, valued at $3,133,261.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP John R. Desjarlais sold 1,280 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $23.50, for a total transaction of $30,080.00. Following the transaction, the vice president now directly owns 186,433 shares of the company’s stock, valued at $4,381,175.50. The disclosure for this sale can be found here. Insiders sold 101,351 shares of company stock worth $2,152,417 over the last ninety days. Corporate insiders own 4.97% of the company’s stock.

Institutional Trading of Xencor

Hedge funds and other institutional investors have recently bought and sold shares of the company. CWM LLC grew its position in shares of Xencor by 498.7% in the 4th quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,147 shares in the last quarter. Parallel Advisors LLC boosted its holdings in Xencor by 303.9% in the fourth quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,015 shares during the period. BluePath Capital Management LLC bought a new stake in Xencor during the third quarter valued at $31,000. China Universal Asset Management Co. Ltd. increased its stake in Xencor by 95.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,548 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 756 shares during the last quarter. Finally, Signaturefd LLC raised its holdings in shares of Xencor by 367.7% during the fourth quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,151 shares during the period.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.